Tianshui Zhongxing Bio-technology Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 2.38, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -94.49 million CNY, which may limit its ability to fund operations or growth without external financing.

In terms of profitability, the company's return on equity (ROE) is 9.5%, and its return on assets (ROA) is 4.73%. These figures are in line with the industry's preferred metrics, indicating that the company is generating returns that are comparable to its peers. The company's gross profit margin is 28.6%, and its operating margin is 15.97%, both of which are key indicators of its efficiency in converting revenue into profit.

The company's revenue is primarily concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risks if market conditions in its primary segment or region deteriorate.

Looking at the company's growth trajectory, the current fiscal year is expected to show a slight increase in revenue, with analysts forecasting a mean EPS of 0.88 CNY compared to the last actual EPS of 0.89 CNY. The company's capital expenditure of -551.55 million CNY indicates a significant investment in long-term assets, which could support future growth.

The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. The company's valuation multiples, including a price-to-earnings ratio of 15.74 and a price-to-book ratio of 1.5, suggest that it is trading at a moderate premium to its book value and earnings.

Recent events, such as analyst estimates and recommendations, indicate a generally positive outlook, with a mean recommendation of 1.50 (strong buy to hold) and a strong-buy count of 1. These signals suggest that the market is cautiously optimistic about the company's future performance.

Tianshui Zhongxing Bio-technology Co Ltd (002772.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now classified as "Food" and its economic sector identified as "Consumer Non-Cyclicals." This reclassification represents a medium-severity change in the company's profile, shifting the analytical framework from a previous undefined state to a specific consumer-oriented context. The significance of this sectoral shift lies in the stability typically associated with consumer non-cyclicals. By anchoring the company within the food industry, the updated classification suggests that Tianshui Zhongxing Bio-technology's revenue streams are likely driven by essential consumer demand rather than discretionary spending, which may influence how investors perceive its resilience during economic fluctuations. In parallel with the sectoral update, the company's risk assessment profile has been initialized with specific metrics. The dilution risk is now rated as "low," indicating a minimal threat of share value erosion from new equity issuance. Conversely, the liquidity risk has been assessed as "medium," suggesting that while the company is not facing immediate solvency issues, there may be moderate constraints on the ease of trading its shares or accessing short-term capital. These changes provide a clearer baseline for evaluating Tianshui Zhongxing Bio-technology, moving from a lack of defined risk and sector data to a structured profile. The combination of a stable sector classification and low dilution risk offers a foundational view of the company's operational and financial environment, although the medium liquidity risk warrants continued monitoring for potential impacts on trading efficiency.